Johnf Dipersio News Today

CHICAGO, IL / ACCESSWIRE / February 22, 2024 / American Society for Transplantation and Cellular Therapy® (ASTCT) presents top awards to leaders in the field of transplantation and cellular therapy at the Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®, Feb. 21-24 in San Anton...

The rising cancer treatment and technology known as CAR-T uses a patient's own blood cells to cure their malignancies.

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 495,600 shares, an increase of 21.2% from the May 15th total of 408,800 shares. Based on an average daily volume of 504,400 shares, the days-to-cover ratio is […]

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) saw a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 408,800 shares, a drop of 56.0% from the April 30th total of 930,000 shares. Currently, 0.9% of the shares of the company are short sold. Based on […]

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 408,800 shares, a drop of 56.0% from the April 30th total of 930,000 shares. Based on an average trading volume of 514,400 shares, the […]

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) – Stock analysts at Wedbush boosted their Q2 2023 earnings per share (EPS) estimates for Magenta Therapeutics in a research report issued on Tuesday, May 16th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.19) for the quarter, up from their […]

Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 1,060,000 shares, a drop of 10.9% from the March 31st total of 1,190,000 shares. Currently, 2.4% of the company’s shares are short sold. Based […]

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.

The standard treatment for patients with multiple myeloma often includes stem cell transplantation in which the patient’s own stem cells are harvested and stored while the patient receives intensive chemotherapy to kill the cancer. Then, the patient’

Adding motixafortide to standard stem cell mobilization therapy for autologous hematopoietic stem cell transplantation (ASCT) significantly improved collection success rates vs standard therapy plus a placebo in a phase 3 trial of patients with multiple myeloma.